Trapani, Francesca

BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 444

Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismLung Cancer Research Studies

Cited by 378

Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer

Amicarella, F., Muraro, M. G., Hirt, C., Cremonesi, E., Padovan, E., Mele, V, Governa, V, Han, J., Huber, X., Droeser, R. A., et al. (2017) · Gut

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 189

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C. A., Albrecht, C., Alpar, D., Arnhof, H., Bergner, O., Bosch, K., et al. (2024) · Nature Cancer

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 76

Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Gerlach, D., Gmachl, M., Ramharter, J., Teh, J., Fu, S.-C., Trapani, F., Kessler, D., Rumpel, K., Botesteanu, D.-A., Ettmayer, P., et al. (2020) · Cancer Research

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 53

Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis

Schlager, S., Salomon, C., Olt, S., Albrecht, C., Ebert, A., Bergner, O., Wachter, J., Trapani, F., Gerlach, D., Voss, T., et al. (2020) · Oncotarget

Lymphoma Diagnosis and TreatmentCell death mechanisms and regulation

Cited by 36

Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Savarese, F., Gollner, A., Rudolph, D., Lipp, J., Popow, J., Hofmann, M. H., Arnhof, H., Rinnenthal, J., Trapani, F., Gmachl, M., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 25

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

Hofmann, M. H., Lu, H., Duenzinger, U., Gerlach, D., Trapani, F., Machado, A. A., Daniele, J. R., Waizenegger, I., Gmachl, M., Rudolph, D., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 20